Navigation Links
New treatment successful for the Mal de Debarquement Syndrome
Date:8/7/2014

People who suffer from a rare illness, the Mal de Debarquement Syndrome (MdDS), now have a chance for full recovery thanks to treatment developed by researchers at the Icahn School of Medicine at Mount Sinai. Their findings were published online in the July issue of Frontiers in Neurology.

People often feel a sensation of movement, called Mal de Debarquement, after they have finished boating, surfing or a sea voyage. The symptoms usually disappear within hours, but in some people, and more frequently in women, symptoms can continue for months or years, causing fatigue, insomnia, headaches, poor coordination, anxiety, depression and an inability to work. Known as the Mal de Debarquement Syndrome (MdDS), the rare condition is marked by continuous feelings of swaying, rocking or bobbing.

"Our study has provided the first effective treatment for this troublesome disorder, and we hope it provides relief to the thousands of people who may be affected worldwide," said Bernard Cohen, MD, the Morris Bender Professor of Neurology at the Icahn School of Medicine at Mount Sinai.

Until now, there has been no effective treatment for MdDS. Diagnostic tests and early research done at Mount Sinai suggested that MdDS was caused by malfunctioning of the vestibule-ocular reflex (VOR), a mechanism in the inner ear that maintains balance and stabilizes the eyes during head movements, said Dr. Cohen.

The new treatment re-adapts the VOR by moving the visual surroundings as the head is slowly rolled from side to side at the same frequency as the subject's symptomatic rocking, swaying or bobbing. In the study, the head roll caused vertical eye movements (nystagmus), and subjects tended to turn to one side when marching in place.

Subjects were rocked or swayed at about one cycle per five seconds. Generally, three to five treatments a day for one week were sufficient to produce a cure, and the movements and associated symptoms disappeared. Side effects of the treatments were negligible. Seventy percent of the 24 subjects that were treated in this study (21 women, three men, mean age 43.3 years) reported either a complete or substantial recovery for a mean follow-up of approximately one year after treatment. Six only had transient improvement, while one did not respond to treatment.

"The work of our team also opens up a new area of research on how the Vestibulo-Ocular Reflex can produce head and body oscillations, and may eventually provide insight into other brain diseases that cause repetitive shaking and tremor of the head and body," Dr. Cohen said.

Mal de Debarquement Syndrome (MdDS) occurs only in a small fraction of those who experience Mal de Debarquement, and has been classified as a rare, disabling disease by the National Institutes of Health (NIH). Exact estimates of its prevalence are not available, but it was present in 1.3 percent of patients at a 'Neuro Otology Clinic' at the University of California, Los Angeles (UCLA). This suggests that there are hundreds of people with this syndrome in the United States and thousands worldwide, Dr. Cohen said.


'/>"/>

Contact: Sasha Walek
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... Super Powder, a ... to on the go individuals and dedicated athletes, continues to transform the nutritional supplement ... with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, ...
(Date:5/30/2016)... Salt Lake City, Utah (PRWEB) , ... May ... ... health insurance reimbursement for small businesses, announced today the publication of an original ... helps business owners and health insurance professionals understand how Zane Benefits complies with ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is ... that has been available via Amazon.com. This new style of nail clipper has ... The jaw opening is approximately 4mm and the actual handle is 2.5mm thick to ...
(Date:5/28/2016)... ... , ... SuperCloset is proud to officially launch our “Helping Veterans Grow ... and obstacles veterans’ need to overcome in order to face their life changes upon ... veteran(s) with a donated SuperCloset product based on the needs and ability of helping ...
(Date:5/28/2016)... ... 28, 2016 , ... After a year and a half of planning the Multiple Pathways ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... Kingdom came together to explore the many pathways individuals use to get into and sustain ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 On ... eliminate viral hepatitis by 2030. At the 69 th ... ever Global Viral Hepatitis Strategy, signalling the greatest global commitment ... a goal of eliminating hepatitis B and C by 2030 ... if reached, will reduce annual deaths by 65% and increase ...
(Date:5/27/2016)... 27, 2016  A new study highlights the necessity of health literacy within the ... the American College of Radiology , a majority of oncology patients undergo imaging screenings ... http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
Breaking Medicine Technology: